Lakefront Biotherapeutics (GLPGF) Total Non-Current Liabilities (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Total Non-Current Liabilities for 14 consecutive years, with $21.8 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 97.52% year-over-year to $21.8 million in Q1 2026; TTM through Mar 2026 was $21.8 million, a 97.52% decrease from a year earlier, with the FY2025 full-year figure at $20.1 million, down 97.95% from the prior year.
• Total Non-Current Liabilities was $21.8 million for Q1 2026 at Lakefront Biotherapeutics, up from $20.7 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $1719.9 billion in Q4 2022 and troughed at $20.7 million in Q4 2025.
• A 5-year average of $133.2 billion and a median of $1.1 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities plunged 99.93% in 2023 and fell 20.83% in 2024, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $1719.9 billion in 2022, then sank by 99.93% to $1.2 billion in 2023, then retreated by 20.83% to $965.7 million in 2024, then tumbled by 97.86% to $20.7 million in 2025, then advanced by 5.38% to $21.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $21.8 million (Q1 2026), $20.7 million (Q4 2025), and $816.5 million (Q3 2025), per Business Quant data.